Skip to main content
$81.90 -$1.08 (-1.3%)

04:00 PM EDT on 06/18/21

BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)

CAPS Rating: 3 out of 5

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Current Price $81.90 Mkt Cap $15.0B
Open $82.54 P/E Ratio 18.67
Prev. Close $81.90 Div. (Yield) $0.00 (0.0%)
Daily Range $81.52 - $82.90 Volume 1,340,779
52-Wk Range $71.35 - $131.95 Avg. Daily Vol. 822,235

Caps

How do you think NASDAQ:BMRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

895 Outperform
51 Underperform
 

All-Star Players

162 Outperform
10 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:BMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

d3ming (69.74)
Submitted January 31, 2014

zzporte

GundersonGroup (27.67)
Submitted November 05, 2012

The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per… More

NASDAQ:BMRN VS S&P 500 (SPY)

Fools bullish on NASDAQ:BMRN are also bullish on:

Fools bearish on NASDAQ:BMRN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BMRN.

Recs

0
Member Avatar StingyHobo (< 20) Submitted: 1/24/2021 7:58:41 PM : Outperform Start Price: $85.86 NASDAQ:BMRN Score: -12.76

From basic research it appears that this is a healthy company that has high value products that will be on the market soon. The only reason their valuation sank so low is because one of their anticipated drugs got delayed on approval. First, the company can thrive without that product. Second, the product was not rejected but delayed. Upon approval this company should once again skyrocket.

Recs

0
Member Avatar AnyaNafNaf (43.03) Submitted: 1/11/2021 1:49:07 PM : Outperform Start Price: $82.61 NASDAQ:BMRN Score: -10.20

Steady company with several products in the pipeline to sell. The drug, that has been delayed, looks promising so far, according to the trials. The stock is likely to close the gap soon.

Recs

0
Member Avatar RCi (53.31) Submitted: 1/10/2021 2:53:36 PM : Outperform Start Price: $83.92 NASDAQ:BMRN Score: -12.22

Late-stage clinical candidates

Leaderboard

Find the members with the highest scoring picks in BMRN.

Score Leader

Jmcq88

Jmcq88 (89.22) Score: +758.20

The Score Leader is the player with the highest score across all their picks in BMRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BreakerBeth 95.69 5/17/2006 Outperform 5Y $12.26 +568.03% +245.70% +322.33 1 Comment
RBBioContest06 47.63 6/1/2006 Outperform 1Y $13.05 +527.59% +248.74% +278.84 1 Comment
DamYankee < 20 9/29/2006 Outperform 1Y $14.41 +468.36% +229.22% +239.13 0 Comment
MellieMel777 40.10 9/29/2006 Outperform 3Y $14.41 +468.36% +229.22% +239.13 1 Comment
taxisvs 51.75 10/2/2006 Outperform NS $15.00 +446.00% +229.85% +216.15 0 Comment
rolloro < 20 10/2/2006 Outperform 3Y $15.00 +446.00% +229.85% +216.15 1 Comment
mgaal < 20 4/30/2007 Outperform 1Y $16.16 +406.81% +193.13% +213.67 0 Comment
phytoremediation < 20 4/30/2007 Outperform 3M $16.16 +406.81% +193.13% +213.67 1 Comment
inthefield 79.65 4/30/2007 Outperform NS $16.16 +406.81% +193.13% +213.67 0 Comment
ggkeith < 20 9/23/2006 Outperform 5Y $15.06 +443.82% +235.56% +208.26 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BMRN.